Statistics for Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma : results from the phase II nonrandomized KEYNOTE-059 study
Total visits
| views | |
|---|---|
| Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma : results from the phase II nonrandomized KEYNOTE-059 study | 60 |
Total visits per month
| views | |
|---|---|
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
File Visits
| views | |
|---|---|
| Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal.pdf | 16 |
Top country views
| views | |
|---|---|
| United States | 40 |
| Chile | 8 |
| Israel | 1 |
| Mexico | 1 |
| Sweden | 1 |
Top city views
| views | |
|---|---|
| Miami | 36 |
| Santiago | 7 |
| Alameda | 2 |
| Campbell | 1 |
| Los Angeles | 1 |
| Sacramento | 1 |
| Tel Aviv | 1 |
| Zapopan | 1 |
| Åkersberga | 1 |